Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($1.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($11.12) by $9.56, Zacks reports. The company had revenue of $1,000 billion for the quarter.
Sonnet BioTherapeutics Stock Up 3.2 %
NASDAQ:SONN traded up $0.05 during midday trading on Friday, hitting $1.59. The company had a trading volume of 47,330 shares, compared to its average volume of 175,227. Sonnet BioTherapeutics has a 52-week low of $1.41 and a 52-week high of $18.72. The stock’s fifty day moving average price is $1.64 and its 200-day moving average price is $2.25.
Wall Street Analysts Forecast Growth
Separately, Chardan Capital decreased their price target on Sonnet BioTherapeutics from $30.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, December 20th.
About Sonnet BioTherapeutics
Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
Read More
- Five stocks we like better than Sonnet BioTherapeutics
- Canada Bond Market Holiday: How to Invest and Trade
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- The Most Important Warren Buffett Stock for Investors: His Own
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for Sonnet BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonnet BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
